Literature DB >> 28706900

Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).

Hasan Fevzi Batirel1.   

Abstract

Surgical techniques for treatment of malignant pleural mesothelioma (MPM) have improved over the decades. The main surgical principle was accepted as macroscopic complete resection. This principle was achieved with extrapleural pneumonectomy (EPP) and extended pleurectomy/decortication (P/D). Mortality and morbidity are higher following EPP with supraventricular arrhythmias, pulmonary embolism, bronchopleural fistula and pulmonary failure being the most common, while prolonged air leak is frequent following P/D. Completion of multimodality treatment was also shown to be a prognostic factor. Many different neoadjuvant and adjuvant protocols were applied with limited effect on prognosis. While locoregional recurrence is more common following P/D, EPP patients typically recur in contralateral hemithorax and abdomen. Hemithoracic radiation following EPP was the only effective technique shown to decrease locoregional recurrence. However, neither surgical technique (EPP vs. P/D), nor types of multimodality treatment protocols were found to be prognostic in MPM. Epithelioid histology, metastasis to extrapleural lymph nodes and completion of multimodality treatment were prognostic in most of the series. In conclusion, based on the current evidence, the choice of a less morbid and mortal procedure (P/D) seems to be the logical choice in the treatment of MPM.

Entities:  

Keywords:  Extrapleural pneumonectomy (EPP); malignant pleural mesothelioma (MPM); pleurectomy/decortication (P/D)

Year:  2017        PMID: 28706900      PMCID: PMC5497106          DOI: 10.21037/atm.2017.03.82

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  29 in total

1.  The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.

Authors:  V W Rusch; S Piantadosi; E C Holmes
Journal:  J Thorac Cardiovasc Surg       Date:  1991-07       Impact factor: 5.209

2.  Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.

Authors:  Martin Utley; Francesca Fiorentino; Tom Treasure
Journal:  Eur J Cardiothorac Surg       Date:  2010-03-30       Impact factor: 4.191

3.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

4.  Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.

Authors:  David Rice; Valerie Rusch; Harvey Pass; Hisao Asamura; Takashi Nakano; John Edwards; Dorothy J Giroux; Seiki Hasegawa; Kemp H Kernstine; David Waller; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

5.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

Authors:  V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  2001-10       Impact factor: 5.209

6.  Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Marc de Perrot; Ronald Feld; Natasha B Leighl; Andrew Hope; Thomas K Waddell; Shaf Keshavjee; B C John Cho
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

7.  Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.

Authors:  Hasan Fevzi Batirel; Muzaffer Metintas; Hale Basak Caglar; Guntulu Ak; Perran Fulden Yumuk; Bedrettin Yildizeli; Mustafa Yuksel
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-09       Impact factor: 5.209

8.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.

Authors:  David J Sugarbaker; Michael T Jaklitsch; Raphael Bueno; William Richards; Jeanne Lukanich; Steven J Mentzer; Yolonda Colson; Phillip Linden; Michael Chang; Leah Capalbo; Elizabeth Oldread; Siyamek Neragi-Miandoab; Scott J Swanson; Lambros S Zellos
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

9.  Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Authors:  Rolf A Stahel; Oliver Riesterer; Alexandros Xyrafas; Isabelle Opitz; Michael Beyeler; Adrian Ochsenbein; Martin Früh; Richard Cathomas; Kristiaan Nackaerts; Solange Peters; Christoph Mamot; Alfred Zippelius; Carlo Mordasini; Clemens B Caspar; Katrin Eckhardt; Ralph A Schmid; Daniel M Aebersold; Oliver Gautschi; Wolfgang Nagel; Michael Töpfer; Jerome Krayenbuehl; Karin Ribi; Ilja Ciernik; Walter Weder
Journal:  Lancet Oncol       Date:  2015-11-02       Impact factor: 41.316

10.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

View more
  8 in total

Review 1.  Extrapleural pneumonectomy: still indicated?

Authors:  Andreas Domen; Lawek Berzenji; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Jan P Van Meerbeeck; Paul E Van Schil
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 2.  Proton beam therapy for malignant pleural mesothelioma.

Authors:  Shahed N Badiyan; Jason K Molitoris; Mingyao Zhu; Erica Glass; Tejan Diwanji; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 3.  Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies.

Authors:  David A Mahvi; Rong Liu; Mark W Grinstaff; Yolonda L Colson; Chandrajit P Raut
Journal:  CA Cancer J Clin       Date:  2018-10-17       Impact factor: 508.702

4.  Time-varying analysis of readmission and mortality during the first year after pneumonectomy.

Authors:  Gregory D Jones; Kay See Tan; Raul Caso; Joseph Dycoco; Bernard J Park; Matthew J Bott; Daniela Molena; James Huang; James M Isbell; Manjit S Bains; David R Jones; Gaetano Rocco
Journal:  J Thorac Cardiovasc Surg       Date:  2020-03-07       Impact factor: 5.209

Review 5.  Multimodality treatment of malignant pleural mesothelioma.

Authors:  Lawek Berzenji; Paul Van Schil
Journal:  F1000Res       Date:  2018-10-22

6.  Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.

Authors:  Xiaoyu Li; Takashi Eguchi; Rania G Aly; Navin K Chintala; Kay See Tan; Marjorie G Zauderer; Francine R Dembitzer; Mary Beth Beasley; Berhane Ghebrehiwet; Prasad S Adusumilli; Ellinor I B Peerschke
Journal:  Front Oncol       Date:  2019-10-11       Impact factor: 6.244

7.  Surgical staging and resection of malignant pleural mesothelioma.

Authors:  Lawrence B Brown; Frank Corl; Shanda H Blackmon
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 3.005

8.  Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma.

Authors:  Giuseppe Mangiameli; Edoardo Bottoni; Umberto Cariboni; Giorgio Maria Ferraroli; Emanuela Morenghi; Veronica Maria Giudici; Emanuele Voulaz; Marco Alloisio; Alberto Testori
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.